Latest news with #SelectMedical
Business Insider
5 hours ago
- Business
- Business Insider
Mizuho Securities Sticks to Their Buy Rating for Select Medical (SEM)
Mizuho Securities analyst Ann Hynes maintained a Buy rating on Select Medical today and set a price target of $18.00. The company's shares closed today at $12.07. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Hynes is a 5-star analyst with an average return of 7.2% and a 57.66% success rate. Hynes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Centene. In addition to Mizuho Securities, Select Medical also received a Buy from Benchmark Co.'s Bill Sutherland in a report issued on August 4. However, on the same day, UBS maintained a Hold rating on Select Medical (NYSE: SEM). The company has a one-year high of $40.98 and a one-year low of $11.65. Currently, Select Medical has an average volume of 1.25M.
Yahoo
5 days ago
- Business
- Yahoo
agilon health (AGL) Q2 Earnings: What To Expect
Healthcare services company Agilon Health (NYSE:AGL) will be announcing earnings results this Tuesday after the bell. Here's what to look for. agilon health beat analysts' revenue expectations by 1.8% last quarter, reporting revenues of $1.53 billion, down 4.5% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. It lost -36,000 customers and ended up with a total of 491,000. Is agilon health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting agilon health's revenue to be flat year on year at $1.47 billion, slowing from the 38.7% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.11 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. agilon health has missed Wall Street's revenue estimates five times over the last two years. Looking at agilon health's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. agilon health is down 25.8% during the same time and is heading into earnings with an average analyst price target of $3.59 (compared to the current share price of $1.73). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Surgery Partners (SGRY) Reports Earnings Tomorrow: What To Expect
Healthcare company Surgery Partners (NASDAQ:SGRY) will be reporting results this Tuesday before market open. Here's what to expect. Surgery Partners met analysts' revenue expectations last quarter, reporting revenues of $776 million, up 8.2% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. Is Surgery Partners a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Surgery Partners's revenue to grow 7.1% year on year to $816.1 million, slowing from the 14.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.14 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Surgery Partners has missed Wall Street's revenue estimates four times over the last two years. Looking at Surgery Partners's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Surgery Partners is down 3.4% during the same time and is heading into earnings with an average analyst price target of $31.08 (compared to the current share price of $21.28). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
Encompass Health (EHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Health care services provider Encompass Health (NYSE:EHC) will be announcing earnings results this Monday afternoon. Here's what you need to know. Encompass Health beat analysts' revenue expectations by 1.7% last quarter, reporting revenues of $1.46 billion, up 10.6% year on year. It was a strong quarter for the company, with an impressive beat of analysts' full-year EPS guidance estimates and a solid beat of analysts' EPS estimates. Is Encompass Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Encompass Health's revenue to grow 9.6% year on year to $1.43 billion, in line with the 9.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.21 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Encompass Health has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.5% on average. Looking at Encompass Health's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Encompass Health is down 9.1% during the same time and is heading into earnings with an average analyst price target of $131.58 (compared to the current share price of $108.53). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
6 days ago
- Business
- Yahoo
Encompass Health (EHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Health care services provider Encompass Health (NYSE:EHC) will be announcing earnings results this Monday afternoon. Here's what you need to know. Encompass Health beat analysts' revenue expectations by 1.7% last quarter, reporting revenues of $1.46 billion, up 10.6% year on year. It was a strong quarter for the company, with an impressive beat of analysts' full-year EPS guidance estimates and a solid beat of analysts' EPS estimates. Is Encompass Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Encompass Health's revenue to grow 9.6% year on year to $1.43 billion, in line with the 9.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.21 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Encompass Health has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.5% on average. Looking at Encompass Health's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Encompass Health is down 9.1% during the same time and is heading into earnings with an average analyst price target of $131.58 (compared to the current share price of $108.53). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
